IE
MENS

Israel Englander’s Jyong Biotech MENS Stock Holding History

Israel Englander’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,590
Closed -$31.4K – 6550
2026
Q1 		$31.4K Sell
14,590
-25,668
-64% -$62.8K ﹤0.01% 5472
2025
Q4 		$159K Buy
40,258
+27,245
+209% +$962K ﹤0.01% 5533
2025
Q3 		$512K Buy
+13,013
New +$468K ﹤0.01% 5056

Other funds holding MENS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Israel Englander's MENS Position: Q2 2026 in Review

Israel Englander sold out of Jyong Biotech (MENS) in Q2 2026, closing a stake of 14,590 shares — an estimated $31.4K sold.

Israel Englander first reported a position in MENS in Q3 2025 and held it in 3 quarters. The position peaked at $512K in Q3 2025. 19 funds tracked by Wall St. Rank hold MENS as of Q2 2026.

  • Israel Englander reported no remaining Jyong Biotech position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 14,590 Jyong Biotech shares in Q2 2026, an estimated $31.4K.
  • Israel Englander first reported a position in Jyong Biotech in Q3 2025 and held it in 3 quarters.
  • Israel Englander's Jyong Biotech position peaked at $512K in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Jyong Biotech as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.